TY - JOUR
T1 - Ocular Inflammation in Behçet Disease
T2 - Incidence of Ocular Complications and of Loss of Visual Acuity
AU - Kaçmaz, R. Oktay
AU - Kempen, John H.
AU - Newcomb, Craig
AU - Gangaputra, Sapna
AU - Daniel, Ebenezer
AU - Levy-Clarke, Grace A.
AU - Nussenblatt, Robert B.
AU - Rosenbaum, James T.
AU - Suhler, Eric B.
AU - Thorne, Jennifer E.
AU - Jabs, Douglas A.
AU - Foster, C. Stephen
N1 - Funding Information:
This study was supported primarily by Grant EY014943 from the National Eye Institute, National Institutes of Health, Bethesda, Maryland (Dr Kempen). Additional support was provided by the Paul and Evanina Mackall Foundation, Philadelphia, Pennsylvania, and Research to Prevent Blindness Inc (RPB), New York, New York. Dr Kempen is a Research to Prevent Blindness James S. Adams Special Scholar Award recipient. Dr Thorne is a Research to Prevent Blindness Harrington Special Scholar Award recipient. Drs Jabs and Rosenbaum are a Research to Prevent Blindness Senior Scientific Investigator Award recipients. Dr Levy-Clarke was previously and Dr Nussenblatt continues to be supported by intramural funds of the National Eye Institute. The authors indicate no financial conflict of interest. Involved in conception and design (R.O.K., J.H.K., C.N., S.G., E.D., G.A.L.-C., R.B.N., J.T.R., E.B.S., J.E.T., D.A.J., C.S.F.); analysis and interpretation (R.O.K., J.H.K., C.W.N.); writing the article (R.O.K., J.H.K.); critical review of the article (R.O.K., J.H.K., C.N., S.G., E.D., G.A.L.-C., R.B.N., J.T.R., E.B.S., J.E.T., D.A.J., C.S.F.); final approval of the article (R.O.K., J.H.K., C.N., S.G., E.D., G.A.L.-C., R.B.N., J.T.R., E.B.S., J.E.T., D.A.J., C.S.F.); data collection (R.O.K., J.H.K., S.G., E.D.); provision of resources (R.O.K., J.H.K., C.N., S.G., E.D., G.A.L.-C., R.B.N., J.T.R., E.B.S., J.E.T., D.A.J., C.S.F.); statistical expertise (J.H.K., C.W.N.); obtaining funding (J.H.K.); literature search (R.O.K., J.H.K.); and administrative, technical, or logistic support (R.O.K., J.H.K., C.N., S.G., E.D., G.A.L.-C., R.B.N., J.T.R., E.B.S., J.E.T., D.A.J., C.S.F.). The SITE Cohort Study was conducted with the approval of the following institutional review boards: University of Pennsylvania Office of Regulatory Affairs (PENN); Johns Hopkins School of Medicine Institutional Review Board no. 3 (Wilmer/JHU); New England Institutional Review Board (MERSI); Massachusetts Eye & Ear Infirmary Institutional Review Board (MEEI); Oregon Health & Sciences University Institutional Review Board (Casey/OHSU); Combined Neurosciences (CNS) Institutional Review Board of the Clinical Center (CC), National Eye Institute. The study was conducted in accordance with the precepts of the Declaration of Helsinki.
PY - 2008/12
Y1 - 2008/12
N2 - Purpose: To estimate the risk of structural ocular complications and loss of visual acuity (VA) in cases of Behçet disease (BD) and to evaluate potential risk and protective factors for these events. Design: Retrospective cohort study. Methods: A total of 168 consecutive patients with BD-associated ocular inflammation treated at five academic center ocular inflammation subspecialty practices were included. Clinical data for these patients were ascertained by standardized chart review. Main outcome measures included VA, structural ocular complications of inflammation, and intraocular pressure (IOP). Results: Over a median follow-up of 1.05 years, the incidence of specific structural complications and IOP disturbances were common: the incidence rate of any ocular complication was 0.45 per eye-year (EY). Rates of loss of VA to 20/50 or worse and to 20/200 or worse were 0.12 per EY and 0.09 per EY, respectively. Risk factors for loss of VA during follow-up were persistent inflammatory activity, presence of posterior synechiae, presence of hypotony, and presence of elevated IOP. In a time-dependent analysis, current activity of ocular inflammation was associated with an increased risk of loss of VA to 20/50 or worse (relative risk [RR], 2.45; 95% confidence interval [CI], 1.1 to 5.5; P = .03) and to 20/200 or worse (RR, 2.67; 95% CI, 1.2 to 5.8; P = .01). Conclusions: Loss of VA and occurrence of ocular complications were common in patients with ocular inflammation associated with BD, even with aggressive therapy. Ongoing inflammation during follow-up, presence or occurrence of posterior synechiae, hypotony, and elevated IOP were associated with an increased risk of loss of VA.
AB - Purpose: To estimate the risk of structural ocular complications and loss of visual acuity (VA) in cases of Behçet disease (BD) and to evaluate potential risk and protective factors for these events. Design: Retrospective cohort study. Methods: A total of 168 consecutive patients with BD-associated ocular inflammation treated at five academic center ocular inflammation subspecialty practices were included. Clinical data for these patients were ascertained by standardized chart review. Main outcome measures included VA, structural ocular complications of inflammation, and intraocular pressure (IOP). Results: Over a median follow-up of 1.05 years, the incidence of specific structural complications and IOP disturbances were common: the incidence rate of any ocular complication was 0.45 per eye-year (EY). Rates of loss of VA to 20/50 or worse and to 20/200 or worse were 0.12 per EY and 0.09 per EY, respectively. Risk factors for loss of VA during follow-up were persistent inflammatory activity, presence of posterior synechiae, presence of hypotony, and presence of elevated IOP. In a time-dependent analysis, current activity of ocular inflammation was associated with an increased risk of loss of VA to 20/50 or worse (relative risk [RR], 2.45; 95% confidence interval [CI], 1.1 to 5.5; P = .03) and to 20/200 or worse (RR, 2.67; 95% CI, 1.2 to 5.8; P = .01). Conclusions: Loss of VA and occurrence of ocular complications were common in patients with ocular inflammation associated with BD, even with aggressive therapy. Ongoing inflammation during follow-up, presence or occurrence of posterior synechiae, hypotony, and elevated IOP were associated with an increased risk of loss of VA.
UR - http://www.scopus.com/inward/record.url?scp=56249131741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56249131741&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2008.06.019
DO - 10.1016/j.ajo.2008.06.019
M3 - Article
C2 - 18708181
AN - SCOPUS:56249131741
SN - 0002-9394
VL - 146
SP - 828
EP - 836
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 6
ER -